Skip to content

Clinical effect of Xian Shi Wendan Decoction on patients with anxiety state ACS after PCI

Based on the theory of "toning blood vessels" this paper discusses the clinical effect of Xian Shi Wendan Decoction on patients with anxiety and ACS after PCI (syndrome of liver stagnation and phlegm obstruction)

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2024000660
Enrollment
Unknown
Registered
2024-11-06
Start date
2023-01-01
Completion date
Unknown
Last updated
2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary heart disease

Interventions

Experimental group:Xian's wendan Decoction and Western medicine basic treatment
Control Group:Xian's wendan placebo and Western medicine basic treatment

Sponsors

Shenzhen Hospital of Integrated Traditional Chinese and Western Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Persons between the ages of 18 and 75 both male and female; (2) Patients who met the diagnostic criteria for acute coronary syndrome and underwent PCI successfully had stable vital signs; (3) Hamilton Anxiety Scale score (=14 points < 29 points) was performed for patients with stable condition after PCI; (4) PHQ-9=9 points; (5) meet the diagnostic criteria of TCM liver stagnation phlegm turbidness; (6) The patient agrees to participate in the study and signs the informed consent.

Exclusion criteria

Exclusion criteria: (1) Patients with poorly controlled hypertension (systolic blood pressure =180mmHg or diastolic blood pressure =100mmHg); (2) Patients with poor blood glucose control (HBA1c > 7.9%) (3) Patients with severe heart failure New York Heart Association (NYHA) Class IV or cardiogenic shock; (4) Pregnant or lactating women; (5) Patients with severe renal insufficiency or liver insufficiency (ALP > 405U/L or glomerular filtration rate < 30ml/min); (6) Patients with malignant tumors; (7) Patients with severe hematopoietic system diseases; (8) Patients with primary anxiety or other mental disorders; (9) Patients with cognitive disorders such as Alzheimer's disease and cerebral infarction; (10) Patients considered unsuitable for enrollment by the investigator.

Design outcomes

Primary

MeasureTime frame
Hamilton Anxiety ScaleHAMA;

Secondary

MeasureTime frame
Serum 5-HT, DA, NE, GABA ;Differential characterization of metabolites in serum;SAQ;WHOQOL-BREF;TLR4 and T lymphoid immune function;

Countries

China

Contacts

Public Contacthuangxiaojing

Shenzhen Hospital of Integrated Traditional Chinese and Western Medicine

839781358@qq.com13760653030

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026